Shares of Audentes Therapeutics Inc (NASDAQ:BOLD) have earned a consensus recommendation of “Buy” from the eighteen research firms that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, three have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $41.66.
Several equities research analysts have commented on the stock. Mizuho reiterated a “buy” rating and issued a $45.00 price target on shares of Audentes Therapeutics in a research report on Wednesday, August 7th. BMO Capital Markets set a $47.00 price target on shares of Audentes Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, May 8th. BidaskClub cut shares of Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday. HC Wainwright set a $48.00 price target on shares of Audentes Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, May 8th. Finally, Zacks Investment Research cut shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st.
In related news, CEO Matthew R. Patterson sold 20,000 shares of Audentes Therapeutics stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $34.04, for a total value of $680,800.00. Following the transaction, the chief executive officer now owns 135,368 shares of the company’s stock, valued at approximately $4,607,926.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Louis G. Lange sold 21,000 shares of Audentes Therapeutics stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $37.79, for a total value of $793,590.00. Following the completion of the transaction, the director now directly owns 290,001 shares in the company, valued at approximately $10,959,137.79. The disclosure for this sale can be found here. Company insiders own 5.30% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of BOLD. Meeder Asset Management Inc. increased its stake in Audentes Therapeutics by 578.5% in the 2nd quarter. Meeder Asset Management Inc. now owns 726 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 619 shares in the last quarter. Aperio Group LLC purchased a new position in Audentes Therapeutics during the 2nd quarter valued at about $46,000. Amundi Pioneer Asset Management Inc. purchased a new position in Audentes Therapeutics during the 4th quarter valued at about $92,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Audentes Therapeutics by 50.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,990 shares of the biotechnology company’s stock valued at $113,000 after acquiring an additional 1,005 shares in the last quarter. Finally, Legal & General Group Plc grew its stake in Audentes Therapeutics by 34.5% during the 4th quarter. Legal & General Group Plc now owns 6,632 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 1,700 shares in the last quarter. 96.72% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ BOLD traded up $0.93 during midday trading on Friday, reaching $33.88. 334,055 shares of the company traded hands, compared to its average volume of 511,680. Audentes Therapeutics has a 52 week low of $17.95 and a 52 week high of $41.65. The stock has a 50-day moving average price of $36.98 and a 200 day moving average price of $35.87. The company has a market cap of $1.55 billion, a price-to-earnings ratio of -9.96 and a beta of 1.70.
Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.08) by $0.07. During the same quarter in the prior year, the firm earned ($0.85) earnings per share. As a group, equities analysts anticipate that Audentes Therapeutics will post -4.25 earnings per share for the current fiscal year.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Recommended Story: Fundamental Analysis – How It Helps Investors
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.